The WISDOM Trial in COPD

Investigators from ARCN at the LungenClinic Grosshansdorf are co-authors on the WISDOM trial, published this week in the New England Journal of Medicine and announced at ERS in Munich.

Results from the “Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM)” trial were announced at the European Respiratory Society in Munich and published this week in the New England Journal of Medicine. The study found that tapered withdrawal of glucocorticoids in moderate-to-severe COPD patients taking long-acting bronchodilators did not result in an increase in exacerbations relative to those who continued glucocorticoid therapy.  Lead author Helgo Magnussen, along with Anne Kirsten and Henrik Watz, all from the DZL ARCN Center, were among the co-authors on the paper.  Other DZL Investigators who contributed to the study are Prof. Dr. Felix Herth of TLRC, Prof. Dr. Claus Neuror, of CPC-M, and Prof. Dr. Claus Vogelmeier of UGMLC.

For more information please see the original manuscript and accompanying editorial in the New England Journal of Medicine.